Navigation Links
Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies and Advances Phase III Plans for cat Allergy T-Cell Vaccine
Date:9/30/2010

biopharmaceutical company focused on allergy, today announced that it has further advanced the clinical development of three of its leading T-cell allergy vaccines.' In recent weeks, Circassia has initiated phase II clinical testing of its grass allergy (hayfever) therapy, begun the final stage of phase II testing with its ragweed allergy treatment and progressed phase III development plans for its cat allergy therapy. This progress builds on four earlier successful phase II studies of Circassia's ToleroMune(R) technology, which scientifically validated the use of novel T-cell vaccines in treating allergies and identified the optimal dosing approach.

Following these advances, Circassia now has four allergy therapies in late-stage development:

1. Cat allergy. The company's most advanced T-cell vaccine is currently completing its final phase II study. The trial, which includes over 200 patients in Canada, is the first to test Circassia's room-temperature-stable ToleroMune formulation. In parallel, Circassia is progressing phase III development plans for its cat allergy therapy, following a positive endorsement from the European Medicines Agency's scientific advice process.

2. Ragweed allergy. Circassia has initiated the final phase II trial with its ragweed allergy ToleroMune therapy. This 275-patient trial builds on a recently completed phase II study, which demonstrated the potential clinical benefits Circassia's T-cell vaccine can offer ragweed allergy sufferers.

3. Grass allergy (hayfever). Circassia recently initiated phase II clinical testing of its grass allergy T-cell vaccine. Results from the study are anticipated in 2011.

4. House dust mite allergy. Circassia's therapy for house dust mite allergy began phase II testing in early 2010. The initial study is near completion.

"These recent clinical advances demonstrate Circassia's commitment to bringing its unique T-cell allergy vaccines to market as rapidly as poss
'/>"/>

SOURCE Circassia Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vaccine
2. Circassia Acquires North American and Japanese Rights to Dopexamine
3. Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing
4. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
5. Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
6. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
7. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
10. Chimerix Initiates Phase 1 Study of CMX157
11. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Since the cloning of Dolly the Sheep over a decade ... promising way to generate human, patient-specific stem cells for therapeutic ... efforts to substitute animal oocytes. However, a new study published ... 2009 issue of Cloning and Stem Cells , a ...
... its 20 years of experience as a leader in ... is offering free microbial identification testing , along ... attendees visiting the Microtest exhibit, #828, at MD&M West ... range of laboratory testing and validation services - and ...
... WALTHAM, Mass., Feb. 2 Repligen Corporation (Nasdaq: ... and Chief Executive Officer, Walter C. Herlihy, Ph.D., will ... Monday, February 9th, 2009 at 11:30 a.m. EST at ... live audio webcast of the presentation will be available ...
Cached Biology Technology:Animal Eggs Not Suitable Substitutes to Produce Stem Cells 2Animal Eggs Not Suitable Substitutes to Produce Stem Cells 3Microtest Labs Offers Free Microbial Identification Testing, Free Shipping on Other Tests, to MD&M West Attendees 2Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST 2
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/17/2014)... 16, 2014 Research and Markets ... the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend ... for medical sensors in biomedical applications. Chemical sensors ... and correct diagnosis during surgical procedures. The Global ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of the ...  report to their offering. One ... in technology. With continuous advances in technology, it ... latest standard that meets the needs and expectations ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... , BIRMINGHAM, Ala. A new study at the University ... and abdominal obesity, which has been linked to an increased ... that in a sample of young adults during a 15-year ... gained weight at a faster rate than others in the ...
... -- CoLucid Pharmaceuticals, Inc., ("CoLucid"), an innovative biotechnology ... disorders, today announced that its investigational first-in-class Neurally ... COL-144), a selective 5-HT1F receptor agonist, was effective ... as documented in a Phase IIb study. Results ...
... the 2010 International Conference on Emerging Infectious Diseases (ICEID), ... Regency, Atlanta, Georgia. The meeting is being organized ... the American Society for Microbiology, the Council of State ... and the World Health Organization. The International Conference ...
Cached Biology News:UAB study confirms link between depression, abdominal obesity 2CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks 22010 International Conference on Emerging Infectious Diseases 2
...
Whole blood is collected from healthy guinea pigs of either sex from US source which are free of visible diseases at time of blood collection. Hemolytic titer: CH50 = 435 units...
... l-[35S]in vitro cell labeling mix, ... *Aqueous solution stabilized with 0.1% ... pyridine 3,4-dicarboxylic acid. *Amino acid ... labeling containing l-[35S]Methionine and l-[35S]Cysteine. ...
...
Biology Products: